| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/23/2009 | US20090186881 1(R)-1-(4-methyl-2-oxo-2,3-dihydro-benzoxazol-6-ylmethyl)-2-oxo-2-[4-(tetrahydropyran-4-yl)-piperazin-1-yl]-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl); calcitonin gene related peptide antagonist; analgesic, antidiabetic agent; migraine or cluster headaches, non-insulin-dependent diabetes |
| 07/23/2009 | US20090186863 Use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug |
| 07/23/2009 | US20090186856 Micronutrient phosphates as dietary and health supplements |
| 07/23/2009 | US20090186840 5-Thioxylopyranose Compounds |
| 07/23/2009 | US20090186814 Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage |
| 07/23/2009 | US20090186813 Chronic treatment regimen using glucagon-like insulinotropic peptides |
| 07/23/2009 | US20090186808 Method and Compound for the Treatment of Valvular Disease |
| 07/23/2009 | US20090186091 Methods of Treating Cardiovascular Disorders Associated with Atherosclerosis |
| 07/23/2009 | US20090186030 Antibodies that bind both bcma and taci |
| 07/23/2009 | US20090186010 Methods for the identification of ikkalfa function and other genes useful for treatment of inflammatory diseases |
| 07/23/2009 | US20090186001 Methods for Treating Ischemic Tissue |
| 07/23/2009 | US20090185979 Integrin Heterodimer and an Alpha Subunit Thereof |
| 07/23/2009 | DE102008005505A1 Use of a pharmaceutical formulation comprising trimagnesium dicitrate salt or trimagnesium dicitrate, to treat pathological calcifications including arteriosclerosis, where the compounds are present in hydrate or anhydrate form |
| 07/23/2009 | DE102008005484A1 Induktion und Förderung der Arteriogenese Induction and promotion of arteriogenesis |
| 07/23/2009 | CA2712443A1 6- and 7-amino isoquinoline compounds and methods for making and using the same |
| 07/22/2009 | EP2080771A2 New interferon beta-like molecules |
| 07/22/2009 | EP2080520A1 Tryptophanyl-tRNA synthetase derived polypeptides useful for the regulation of angiogenesis |
| 07/22/2009 | EP2079738A2 7-azaindole derivatives as c-met kinase inhibitors |
| 07/22/2009 | EP2079709A1 Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals |
| 07/22/2009 | EP2079695A2 Phenylurea compounds as soluble epoxide hydrolase inhibitors |
| 07/22/2009 | EP2079688A1 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| 07/22/2009 | EP2079683A2 Di-fluoro containing compounds as cysteine protease inhibitors |
| 07/22/2009 | EP2079486A2 Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| 07/22/2009 | EP2079463A1 Crystalline forms of aliskiren hemifumarate |
| 07/22/2009 | EP2079451A1 Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory |
| 07/22/2009 | EP1694292B1 Therapeutic foam comprising a sclerosing solution and a low quanitiy of gaseous nitrogen |
| 07/22/2009 | EP1605040B1 Monocyte-origin multipotent cell momc |
| 07/22/2009 | EP1492761B1 Amino acids with affinity for the alpha-2-delta-protein |
| 07/22/2009 | EP1453528B1 Compositions containing curcuma extracts for the treatment of neurocerebrovascular disorders |
| 07/22/2009 | EP1392680B1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
| 07/22/2009 | EP1392337B2 Pharmaceutical formulation consisting of a plant dry extract with a calcium coating |
| 07/22/2009 | EP1391456B1 2-iminoimidazole derivatives |
| 07/22/2009 | EP1244455B1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 07/22/2009 | EP1220922B1 Method of identifying a compound with efficacy in the treatment of chronic inflammatory diseases |
| 07/22/2009 | EP1133517B1 INTRANUCLEAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| 07/22/2009 | EP1115390B1 Hydroxamate-containing cysteine and serine protease inhibitors |
| 07/22/2009 | CN101486766A Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 07/22/2009 | CN101486682A N3 alkylated benzimidazole derivatives as MEK inhibitors |
| 07/22/2009 | CN101486679A 5HT2c receptor modulators |
| 07/22/2009 | CN101486678A 5HT2C receptor modulators |
| 07/22/2009 | CN101486677A 5HT2c receptor modulators |
| 07/22/2009 | CN101485664A 5HT2c receptor modulators |
| 07/22/2009 | CN100516037C Nitrooxyderivatives of cyclooxygenase-2 inhibitors |
| 07/22/2009 | CN100516024C Amino-propanol derivatives |
| 07/22/2009 | CN100515497C Liposomal delivery of vitamin E based compounds |
| 07/22/2009 | CN100515487C Chinese traditional medicine for treating cardiovascular disease |
| 07/22/2009 | CN100515439C Chinese medicinal preparation for cardio-cerebral blood vessel diseases and its making method |
| 07/22/2009 | CN100515427C self emulsifying soft capsule of breviscapine and its preparation |
| 07/22/2009 | CN100515422C Composition containing benzamidine derivative and method for stabilizing benzamidine derivative |
| 07/21/2009 | USRE40861 4-Trimethylammonium-3-(nonylcarbamoyl)-aminobutyrate; hypoglycemic agents; antidiabetic agents; antiischemic agents; congestive heart failure; obesity |
| 07/21/2009 | US7563811 3-(2-Cyanophenyl)-5-(2-methoxyphenyl)-1-phenyl-1,2-dihydropyridin-2-one; antagonists of AMPA and kainate receptors; neuroprotectants; neurodegenerative diseases; Alzheinmer's disease; antiepileptic agents; antispasmodic agents; anxiolytic agents; ddrug abuse; nervous sytem disorders; antihypoxic agents |
| 07/21/2009 | US7563793 Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents |
| 07/21/2009 | US7563790 Pyridazine derivatives |
| 07/21/2009 | US7563782 Optically active stereoisomer of efonidipine analogs; R-configuration of the 4-position on dihydropyridine ring; kidney insufficiency; hypercardia; congestive heart failure; cardiomyopathy; arterial sclerosis; antifibrillatory/antiarrhythmia agents; cardiovascular disorders; antiedemic/antiinflammatory |
| 07/21/2009 | US7563778 Antisense oligonucleotide preparation method |
| 07/21/2009 | US7563765 Histidine-rich glycoprotein |
| 07/21/2009 | US7563582 Identifying chemical compounds which are capable of modulating the interaction between vasodilator-stimulated phosphoprotein and zyxin |
| 07/21/2009 | US7563467 Use of an Opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells |
| 07/21/2009 | US7563459 Administering a glycoconjugated asialoorosomucoid and the stem cell to the mammal for drug delivering to a target tissue; regenerating heart tissue; tissue-targeted therapy, gene therapy |
| 07/21/2009 | CA2470809C 6-amino-morphinan derivatives, method of manufacturing them and their application |
| 07/21/2009 | CA2387486C Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 07/21/2009 | CA2386215C Method for treatment of chronic venous insufficiencies using an extract of red vine leaves |
| 07/21/2009 | CA2382098C Sustained-release, oral pharmaceutical forms of administration |
| 07/21/2009 | CA2379972C Prodrug of an ice inhibitor |
| 07/21/2009 | CA2367921C Bicyclic heterocycles, processes for their preparation and their use as herbicides and pharmaceutical agents |
| 07/16/2009 | WO2009089547A1 Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| 07/16/2009 | WO2009089545A1 Synthetic triterpenoids and methods of use in the treatment of disease |
| 07/16/2009 | WO2009089093A1 Thyroid hormone receptor agonists |
| 07/16/2009 | WO2009089053A1 Oligomer-guanidine class conjugates |
| 07/16/2009 | WO2009088997A1 Lactam inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 07/16/2009 | WO2009088786A1 Rna interference for the treatment of heart failure |
| 07/16/2009 | WO2009088531A1 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| 07/16/2009 | WO2009088530A1 Pterin analog for treating bh4 responsive condition |
| 07/16/2009 | WO2009088063A1 Pharmaceutical composition, use of 2-iminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases |
| 07/16/2009 | WO2009088006A1 Combined pharmaceutical agent |
| 07/16/2009 | WO2009087949A1 Compound having heterocyclic ring, and use thereof |
| 07/16/2009 | WO2009087649A1 Renin inhibitors |
| 07/16/2009 | WO2009087238A2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies |
| 07/16/2009 | WO2009087116A1 Use of spp100 for the treatment of acute mi |
| 07/16/2009 | WO2009086685A1 An alginic acid with low molecular weight, its salts, uses, preparative methods, pharmaceutical compositions and foods |
| 07/16/2009 | WO2009064023A8 Skin moisturizer, blood circulation promoter, and external preparations for the skin containing the skin moisturizer and the blood circulation promoter |
| 07/16/2009 | WO2009046860A3 Use of dago as a therapeutic agent |
| 07/16/2009 | WO2009046859A3 Use of af12198 and dago as therapeutic agents |
| 07/16/2009 | WO2009040035A3 Use of a peptide as a therapeutic agent |
| 07/16/2009 | WO2009039990A3 Use of icam peptide as a therapeutic agent |
| 07/16/2009 | WO2009039974A3 Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 07/16/2009 | WO2009033817A3 Use of the combination of the hcv-1 e2 protein (484-499) and the human pancreatic polypeptide as a therapeutic agent |
| 07/16/2009 | WO2009033766A3 Use of a peptide as a therapeutic agent |
| 07/16/2009 | WO2008131859A3 Use of cyclically substituted furopyrimidine derivatives for treating pulmonary arterial hypertonia |
| 07/16/2009 | WO2008131858A3 Use of acyclically substituted furopyrimidine derivatives for treating pulmonary arterial hypertonia |
| 07/16/2009 | WO2005011680A8 Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity |
| 07/16/2009 | US20090182059 Injectable viscous medicinal preparation comprising ethanol and an x-ray opaque fat-soluble compound |
| 07/16/2009 | US20090182057 Deuterated aminoglycidal compounds |
| 07/16/2009 | US20090182045 Use of aminaphtone for the preparation of a medicament for treating arteriopathies |
| 07/16/2009 | US20090182037 Cognitive Function |
| 07/16/2009 | US20090182033 Cyclic Amine Derivatives and Their Uses |
| 07/16/2009 | US20090182030 Process for the preparation of amorphous calcium salt of atorvastatin |
| 07/16/2009 | US20090182027 Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
| 07/16/2009 | US20090182008 Crystalline forms of pitavastatin calcium |
| 07/16/2009 | US20090182007 Organic compounds |